Post Transplant Cyclophosphamide Following Myeloablative TBI As a Conditioning Regimen for High-Risk Patients with AML Who Relapse after Transplant with Busulfan-Containing Regimen
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.399
Abstract: Introduction Allogeneic HSCT (alloHSCT) offers a potential cure for patients with AML; however, 40% of AML patients receiving alloHSCT will experience relapsed disease. Second alloHSCT can offer the best long-term survival but is associated with… read more here.
Keywords: post transplant; patients aml; busulfan containing; transplant ... See more keywords